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Hepatocellular carcinoma (HCC) is themost commonprimary liver tumour (80–90%) and representsmore than 5.7%of all cancers.
Although in recent years the therapeutic options for these patients have increased, clinical results are yet unsatisfactory and the
prognosis remains dismal. Clinical or molecular criteria allowing a more accurate selection of patients are in fact largely lacking.
Lactic dehydrogenase (LDH) is a glycolytic key enzyme in the conversion of pyruvate to lactate under anaerobic conditions. In
preclinical models, upregulation of LDH has been suggested to ensure both an efficient anaerobic/glycolytic metabolism and a
reduced dependence on oxygen under hypoxic conditions in tumour cells. Data from several analyses on different tumour types
seem to suggest that LDH levels may be a significant prognostic factor. The role of LDH in HCC has been investigated by different
authors in heterogeneous populations of patients. It has been tested as a potential biomarker in retrospective, small, and nonfocused
studies in patients undergoing surgery, transarterial chemoembolization (TACE), and systemic therapy. In the major part of these
studies, high LDH serum levels seem to predict a poorer outcome.We have reviewed literature in this setting trying to resume basis
for future studies validating the role of LDH in this disease.
1. Introduction
Hepatocellular carcinoma (HCC) is the most common pri-
mary liver tumour (80–90%) and represents more than 5.7%
of all cancers. HCC incidence has risen to become the 5th
commonest malignancy worldwide and the third leading
cause of cancer-related death, after lung and stomach cancer.
The estimated incidence of new cases is about 500,000–
1000,000 per year, causing 600,000 deaths globally per year
[1].
In the Western world, over 90% of HCC cases occur in
cirrhotic liver, but globally, about 20% of HCC is not associ-
ated with any form of cirrhosis. In these cases, the etiology
remains unknown. Main risk factors for the development
of HCC can be classified into viral (chronic hepatitis B and
hepatitis C), toxic (alcohol, aflatoxin), metabolic (diabetes,
hemochromatosis, and nonalcoholic fatty liver disease), and
immune-related (autoimmune hepatitis and primary biliary
cirrhosis) [2] factors.
Chronic hepatitis and cirrhosis lead to a stepwise process
that involves activation of oncogenes and inactivation of
tumour suppressor genes through genetic and epigenetic
alterations until HCC develops [2].
One particularly important characteristic of HCC in
clinical practice is hypervascularization that modifies itself
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Figure 1: Effect of hypoxic microenvironment on metabolism of tumour cell. Under hypoxia conditions, VHL (Von Hippel Lindau
suppressor) dissociates from subunit alpha of HIF-1. Thus, HIF-1𝛼 binds the beta subunit and promotes the nuclear transcription of several
target genes (e.g., LDH) implicated in tumour angiogenesis, cell proliferation, and metabolism.
widely during the carcinogenesis process [3]. Several angio-
genic proteins that influence neoangiogenesis and conse-
quently tumour progression, high rate of metastasis, and bad
prognosis of HCC have been identified [4–8].
However, the mechanism of neovascularization during
HCC development is still not clear.
Liver tumours display a vasculature less dense than
the normal liver. Some immature liver tumour vessels are
excessively leaky and have abnormal blood flow. This results
in hypovascular areas and severe hypoxia and/or necrosis.
Hypoxia may promote growth of HCC and progression and
resistance to therapies.
Hypoxia represents a clinical biological mechanism for
treatment resistance in cancer cells via the formation of
new blood vessels. Furthermore, a growing body of evidence
indicates that hypoxia might actually promote cancer devel-
opment.
Lactic dehydrogenase (LDH), which is a glycolytic
enzyme, composed of four polypeptide chains, each one
encoded by separate gene (M and H), exists in various types
in human tissues and neoplasms. LDH is a key enzyme in the
conversion of pyruvate to lactate under anaerobic conditions
[9]. Five isoforms of LDH have been identified as a result of
the five different combinations of polypeptide subunits [10].
LDH is typically released from necrotic cells. In several
preclinical models investigating the role of tumour hypoxic
microenvironment, a correlation between high tumour vol-
ume, high percentage of necrosis, high tumour LDH expres-
sion, and high serum LDH levels was, in fact, demonstrated.
Upregulation of LDH has been suggested to ensure both
an efficient anaerobic/glycolytic metabolism and a reduced
dependence on oxygen under hypoxic conditions in tumour
cells.
The biological link between hypoxia, LDH levels, and the
tumour-driven angiogenesis pathway through the abnormal
activation of the hypoxia inducible factor-1 (HIF-1) is well
established (Figure 1). The biological activity of HIF-1 is
determined by the expression and activity of the HIF-1𝛼
subunit [11]. HIF-1𝛼 is an essential factor that upregulates
a series of genes involved in glycolytic energy metabolism,
angiogenesis, erythropoiesis, and cell survival [12]. Hypoxia
in the tumour microenvironment is sufficient to activate
HIF-dependent expression of several downregulated genes
[13]. These include those encoding for vascular endothelial
growth factor, erythropoietin, andmany enzymes involved in
glucose, iron, and nucleotide metabolism [14].
Data from several analyses on different cancers seem to
suggest that LDH levelsmay be a significant prognostic factor.
In colorectal cancer patients, LDH upregulation was in
fact associated with an increased risk of nodal and distant
metastases and high LDH serum levels have been shown to
correlate with a decreased median overall survival [15–21].
A strong association between the expression of LDH
and an aggressive phenotype has also been demonstrated in
gastric cancer [22] and pancreatic cancer [23].
The role of LDH in HCC has been investigated by
different authors in heterogeneous populations of patients.
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The aim of this work is to review the literature in this
setting.
2. LDH in HCC Treated with Surgery
Although surgery remains a frequently used curative therapy
for HCC, long term prognosis after liver resection remains
unsatisfactory, due to high disease relapse incidence. Tumour
recurrence may originate from either intrahepatic metastasis
of primary HCC or de novo carcinogenesis from the remnant
cirrhotic liver [24].
Early HCC recurrence after hepatectomy is associated
with worse clinical outcome. Identification of patients at
high risk for early disease relapse may help improving the
prognosis of this population by surveillance and well-timed
treatment of recurrent disease. Although several studies
suggested factors related to tumour [24, 25] and to treatment
[26, 27] as risk factors for early recurrence of HCC, the use
of these parameters is technically problematic and cannot be
easily used to predict recurrence risk in daily practice.
LDH serum levels as prognostic factor were investigated
in different studies in early HCC patients treated with hepatic
resection.
In a retrospective study on 200 patients treated with
curative hepatic resection, Wang et al. [28] evaluated sev-
eral serum and clinical factors collected at baseline before
treatment. Patients were divided according to the median
recurrence free survival (RFS) in early recurrence group (ER)
and nonearly recurrence group (non-ER). At multivariate
analysis, five independent adverse prognostic factors for early
recurrence were identified: LDH (HR = 1.711, 95% CI =
1.170–2.502, and 𝑝 = 0.006), aspartate aminotransferase
(AST)/alanine aminotransferase (ALT) ratio (HR = 1.769,
95% CI = 1.180–2.540, and 𝑝 = 0.006), alpha-fetoprotein
(AFP) (HR = 2.079, 95% CI = 1.221–3.542, and 𝑝 = 0.007),
resection margin (HR = 2.354, 95% CI = 1.490–3.719, and
𝑝 < 0.001), and TNM stage (HR = 2.164, 95% CI = 1.463–
3.201, and 𝑝 < 0.001).
The role of serum presurgery LDH levels was confirmed
in another larger study (323 patients) by Hu et al. [29].
Patients were categorized as high LDH (>240U/L) and low
LDH group (≤240U/L). Significant differences in tumour
size, capsulation, tumour number, vascular invasion, and
TNM stage were observed between these two groups (𝑝 <
0.05). The 1-, 3-, 5-year disease-free survival (DFS) (24.3%,
13.5%, and 12.2% versus 51.2%, 36.3%, and 32.1%; 𝑝 < 0.001)
and overall survival (45.9%, 28.4%, and 24.3% versus 78.3%,
51.8%, and 43.7%; 𝑝 < 0.001) of HCC patients in the LDH
> 240U/L group were poorer than those in the LDH ≤
240U/L group. Multivariate analysis demonstrated that LDH
> 240U/L served as an independent prognostic indicator of
worse disease-free survival (HR = 1.711, 95%CI = 1.275–2.297,
and 𝑝 < 0.001) and overall survival (HR = 1.568, 95% CI =
1.144–2.149, and 𝑝 = 0.005). Stratification analysis showed
that LDH exhibited a greater predictive value for DFS andOS
in HCC patients with AFP < 200 ng/mL.
Although these studies have included heterogeneous
populations of patients, LDH serum levels emerge as a useful
prognostic marker after liver resection.
3. HCC Treated with Transarterial
Chemoembolization (TACE)
Surgery is the only potentially curative treatment for HCC;
unfortunately, most patients in Western countries present
with an intermediate or advanced HCC at diagnosis with the
consequent impossibility of undergoing curative treatments.
These patients are therefore candidates to palliative therapies
such as arterial embolization, chemoembolization (TACE),
and systemic treatment [30]. TACE represents a crucial treat-
ment option for HCC; however, comparing clinical findings,
results are often hampered by the considerable variability
in patients’ selection criteria and modalities of execution
of therapy [31–34]. However, global results for TACE are
still insufficient, with only a small proportion of patients
benefiting from these procedures.Themolecular mechanism
that accounts for treatment failure is not clear [35, 36]. It
is possible that some adaptive responses to hypoxia may
represent a key factor for resistance. Starting from these
assumptions, the role of LDH has also been evaluated in this
category of patients.
Kohles et al. showed a possible prognostic role for
pretreatment LDH serum levels in HCC patients undergoing
TACE [37]. Levels of liver-specific, tumour-related, and cell
death biomarkers were analyzed and correlated with overall
patient survival on 50 prospectively and consecutively HCC
patients undergoing TACE. Serum levels were collected
before and 24 hours after TACE application. At univariate
analysis, high levels of cytokeratin 19-fragments (CYFRA
21-1), AFP, and low cholinesterase (CHE) levels measured
before and 24 hours after TACE were correlated with unfa-
vorable outcome. Further high pretherapeutic LDH,AST, and
bilirubin levels as well as high 24-hour C-reactive protein
values were associated with poor survival. At multivariate
analysis of clinical and only pretherapeutic biomarkers,
AFP, CHE, and LDH have been shown to be independent
prognostic parameters. When additionally 24-hour values
were included, CHE (24 h) and AFP (24 h) were the strongest
independent prognostic biomarkers with a slightly higher
prognostic power.
In this setting, the role of LDH was evaluated also by our
group in a retrospective study [38].We analyzed a population
of 114 HCC consecutive patients, treated with TACE from
2002 to 2010, at our institution. Patients were classified
according to ECOG PS (Eastern Cooperative Oncology
Group performance status) and were staged using different
staging systems: Child-Pugh, BCLC, Okuda, MELD (Model
for End-Stage LiverDisease), andMELD-Na (Model for End-
Stage Liver Disease, Sodium).We recorded LDH serum levels
before (within 1 month prior to treatment) and after (within
one month after) treatment.
Patients were divided into two groups, according to
LDH serum concentration registered before TACE. First
group included patients with pretreatment LDH ≤ upper
normal limit of 450U/L (group A), whereas the other group
included patients with pretreatment LDH > 450U/L (group
B). Patients were, also, classified according to any variation
in LDH serum levels before and after treatment (increased
versus decreased).
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In patients with LDH values below 450U/L, median
time to progression (TTP) was 16.3 months, whereas it was
10.1 months in patients above the cut-off (𝑝 = 0.0085).
Accordingly, median overall survival (OS) was 22.4 months
and 11.7 months in groups A and B, respectively (𝑝 = 0.0049).
In patients with decreased LDH values after treatment,
median TTP was 12.4 months, and median OS was 22.1
months, whereas TTP was 9.1 months and OS was 9.5 in
patientswith increased LDH levels (TTP:𝑝 = 0.0087; OS:𝑝 =
0.0001). No statistically significant differences were found
between the groups of patients for all clinical characteristics
analyzed (gender, median age, performance status ECOG,
staging systems, and type of TACE performed).
From these experiences, although it is based on small
series, it is clear that patients stratification may represent
a crucial factor for the choice of the appropriate treatment
strategy for the appropriate patient. LDH serum levels have
established the potential to predict clinical outcome and
consequently to lead to better patients selection in this clinical
scenario as well.
4. LDH in HCC Treated with
Systemic Therapies
In the last few years, the introduction of sorafenib, an oral
multityrosine kinase inhibitor (TKI) for the treatment of
advanced HCC patients, changed the clinical landscape for
these tumours and now represents the standard of care [39–
42]. However, a large proportion of patients still do not seem
to benefit from such a treatment approach and are therefore
exposed to unnecessary toxicity [39–42].
Clinical or molecular criteria allowing a more accurate
selection of resistant/responder tumours are in fact largely
lacking, although they would be obviously crucial for an
optimal management of these patients in the clinical practice
[43].
In preclinical studies, high levels of LDHwere reported to
predict resistance to several tyrosine kinase inhibitors (TKI),
including sorafenib [44].
It has been demonstrated that the inhibition of LDH
production with oxamic acid in cancer cell lines potentiated
the antiproliferative activity of tyrosine kinase inhibitors,
such as sorafenib. The effect of high LDH levels on TKI low
activity may be explained by a competition between ATP and
TKIs inhibition at the ATP enzymatic site on the protein
kinases target of their activity. LDH catalyzed the final step
in the glycolytic pathway, the conversion of pyruvate and
NADH to lactate and NAD+, determining the maintenance
of glycolytic flow, and, consequently, the production of ATP.
In cancer cells, in hypoxic conditions, in which anaerobic
glycolysis is the main metabolic pathway to meet the energy
request, the inhibition of LDH could interfere with this
process, causing the depletion of ATP and therefore a lower
competition against TKIs inhibitors.
On this basis, we have conducted a retrospective study
to evaluate the clinical role of LDH in 78 Child-Pugh A
advanced HCC patients treated with sorafenib [45].
We have recorded LDH serum levels before (within 1
month prior to the start of sorafenib treatment) and after
(within one month after the end of sorafenib treatment)
treatment. The cut-off point with the highest sensitivity and
specificity for estimating pretreatment LDH serum levels as a
function of treatment clinical activity was set after ROC curve
analysis at ≤407U/L for both PFS and OS.
At univariate analysis, in patients with LDH values below
the cut-off, median PFS was 6.7 months, whereas it was 1.9
months in patients above the cut-off (HR = 2.79, 95% IC =
1.27–6.15, and 𝑝 = 0.0002). Similarly, median OS was 13.2
months and 4.9 months in the two groups (HR = 2.74, 95%
IC = 1.22–6.16, and 𝑝 = 0.0006). In patients with decreased
LDH values after treatment, median PFS was 6.8months, and
median OS was 21.0 months, whereas PFS was 2.9 months
andOS was 8.6 months in patients with increased LDH levels
(PFS: HR = 0.48, 95% IC = 0.27–0.84, and 𝑝 = 0.0087;
OS: HR = 0.42, 95% IC = 0.23–0.65, and 𝑝 = 0.0035). At
multivariate analysis of LDH serum levels before treatment,
the variation after treatment and BCLC stage emerged as
independent prognostic factors predicting outcome in terms
of PFS (𝑝 = 0.0197, HR = 0.71; 𝑝 = 0.0201, HR = 0.19; and
𝑝 = 0.0016, HR = 0.35, resp.) and OS (𝑝 = 0.0011, HR = 0.69;
𝑝 = 0.0039, HR = 0.24; and 𝑝 = 0.0051, HR = 0.39, resp.).
Another Italian study tried to verify the role of LDH in
this setting. Analysis on a population of 97 HCC patients
treated with sorafenib, part of the ITA.LI.CA (Italian Liver
Cancer) database, seems to contest our findings [46].
Patients with LDH values above (𝑛 = 45) and below
(𝑛 = 52) the cut-off (297U/L) showed equalOS (12.0months)
and TTP (4.0 months) values. Data on LDH levels during
sorafenib treatmentwere reported for 10 patients. LDHvalues
decreased in 3 patients (mean difference = −219U/L) who
also reported a prolonged OS and TTP versus those with
unmodified/increased LDH (OS: NE (not evaluated) versus
8.0 months, 𝑝 = 0.0083; TTP: 19.0 versus 3.0 months, 𝑝 =
0.008).
In this study, the clinical benefits of sorafenib do not seem
to be influenced by baseline LDH levels; however, a decreased
LDH concentration during sorafenib might be associated
with improved clinical outcomes.
5. Other Studies on Heterogeneously
Treated Populations
Other studies had evaluated the role of LDH in HCC patients
not selected for the treatment received.
In a retrospective analysis on 273 HCC patients treated
with different therapies (resective surgery, transarterial
chemoembolization, sorafenib, and radiotherapy) by Yang et
al., patients were divided into two groups: death and alive at
the time of the study [47]. Among the liver function tests,
levels of alanine aminotransferase (AST), gamma-glutamyl
transferase (GGT), alkaline phosphatase (ALP), and LDH
were statistically higher in patients with death outcome (all
𝑝 < 0.05).
At global multivariate survival analysis, of all clini-
cal and serological factors evaluated, ALT, GGT, LDH,
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carcinoembryonic antigen (CEA) levels, andBarcelonaClinic
Liver Cancer (BCLC) stage were significantly associated with
HCC overall survival (HR = 1.01, 95% CI = 1.002–1.017, and
𝑝 = 0.01; HR = 1.003, 95% CI = 1.001–1.004, and 𝑝 < 0.001;
HR = 1.003, 95% CI = 1.002–1.005, and 𝑝 < 0.001; HR = 1.015,
95% CI = 1.005–1.025, and 𝑝 = 0.003; and HR = 2.428, 95%
CI = 1.458–4.044, and 𝑝 = 0.001, resp.).
Another larger retrospective analysis, evaluating clinical e
biological factors, was conducted on a South Korean popula-
tion of 743 HCC patients [48]. Onmultivariate analysis, LDH
<450 IU/L and other factors like age >50 years, CLIP score
<3, ALP <120U/L, CRP <0.8mg/dL, tumour size <6 cm,
no distant metastasis, and curative treatment modality were
predictors for 1-year survival.
6. Conclusions
In the investigation of predictive and prognostic factors
for relatively rare clinical conditions such as HCC, finding
data based on large and homogeneous series is particularly
challenging. Furthermore, HCC is a complex disease; in
most cases, two pathologic conditions, the tumour and the
underlying liver disease, coexist in the same patient and have
a predominant influence on clinical outcome.
All studies reported are retrospective and, in most of
them, patients enrolled were in different tumour and liver
function stages. Patients were stratified according to different
characteristics in each study and data were collected in
multicentre series in a large amount of time.
Moreover, the major parts of the studies reviewed are
not designed to validate the LDH role. But LDH is studied
among other serumor clinical factors, trying to find out some
potential prognostic markers.
Among all studies taken into account, statistical methods
are not reproducible. For example, themethod used to choose
the cut-off to divide population into high or low LDH is
different in each study. Thus, it is possible that the potential
role of LDH could be underestimated.
Despite all criticism cited, LDH seems to show a potential
clinical role. It should be important to try to validate the role
of LDH in clinical practice. In fact, LDH could be considered
an ideal biomarker, easily obtained in every laboratory,
reproducible, and low costing.
Prospective, upfront stratified, LDH-based trials are
needed to confirm the power of this marker as predictive and
prognostic factor in HCC patients.
After these confirmations, we believe that LDH should be
considered as a relevant biological variable to be included in
the baseline setup of HCC patients, with the aim to better
stratify patients included in clinical trials and to better define
the most appropriate therapeutic strategy.
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